We report the case of a 64-year-old patient who developed autoimmune hemolytic anemia with thrombocytopenia and acute renal failure shortly after the infusion of the 11th cycle of adjuvant chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX 4), and was successfully treated by means of plasmapheresis, corticosteroids and dialysis. To the best of our knowledge, only seven other cases have been described in the literature, but we believe this serious adverse event induced by oxaliplatin is more frequent than this would suggest. © 2007 Lippincott Williams & Wilkins, Inc.

Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report / Buti, S.; Ricco, M.; Chiesa, M. D.; Copercini, B.; Tomasello, G.; Brighenti, M.; Passalacqua, R.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 18:3(2007), pp. 297-300. [10.1097/CAD.0b013e3280102f4b]

Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report

Buti S.
;
Copercini B.;Tomasello G.;Brighenti M.;
2007-01-01

Abstract

We report the case of a 64-year-old patient who developed autoimmune hemolytic anemia with thrombocytopenia and acute renal failure shortly after the infusion of the 11th cycle of adjuvant chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX 4), and was successfully treated by means of plasmapheresis, corticosteroids and dialysis. To the best of our knowledge, only seven other cases have been described in the literature, but we believe this serious adverse event induced by oxaliplatin is more frequent than this would suggest. © 2007 Lippincott Williams & Wilkins, Inc.
2007
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report / Buti, S.; Ricco, M.; Chiesa, M. D.; Copercini, B.; Tomasello, G.; Brighenti, M.; Passalacqua, R.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 18:3(2007), pp. 297-300. [10.1097/CAD.0b013e3280102f4b]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2912862
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 25
social impact